Results 71 to 80 of about 5,351 (123)

Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections

Antibiotics
Acinetobacter baumannii has emerged as a pressing challenge in clinical practice, mainly due to the development of resistance to multiple antibiotics, including colistin, one of the last-resort treatments.
Andria Papazachariou, Renatos-Nikolaos Tziolos, Stamatis Karakonstantis, Petros Ioannou, George Samonis, Diamantis P. Kofteridis   +5 more
doaj   +1 more source

Avaliação da suscetibilidade a sulbactam-durlobactam e sua combinação com meropenem em isolados do complexo Acinetobacter baumannii provenientes de hemoculturas [PDF]

Introdução: Acinetobacter baumannii (AB) é um importante patógeno nosocomial associado a resistência a múltiplos antibióticos, particularmente carbapenêmicos.
Galvão, Mileny Rosalina
core  

Self‐Assembling Hydrogel‐Based Controlled Delivery of Sulbactam–Durlobactam and Cefiderocol Against Carbapenem‐Resistant Acinetobacter baumannii

Carbapenem‐resistant Acinetobacter baumannii (CRAB) has emerged as a major global healthcare threat because of its multidrug resistance, biofilm‐forming ability, and ...
R. Sowmya, Krithika Shree Sivasuriyan, S. Karthick Raja Namasivayam, Amrish Varshan G.S   +3 more
core   +1 more source

Μελέτη νεότερου αναστολέα β-λακταμασών σε ανθεκτικά στις καρβαπενέμες στελέχη Acinetobacter baumannii

, 2022
ΕΙΣΑΓΩΓΗ: Το Acinetobacter baumannii αποτελεί κύρια αιτία λοιμώξεων σχετιζόμενων με χώρους υγειονομικής περίθαλψης, εξαιτίας της επιμονής του ως αποικιστή στο νοσοκομειακό περιβάλλον και της ικανότητας του να αποκτά υψηλού επιπέδου αντοχή.
Petropoulou Dimitra, Πετροπούλου Δήμητρα   +1 more
core   +1 more source

Re: Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates : author's response

Authors' reply to : Veeraraghavan B, Walia K, Egli A. Re: 'Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et al.
Le Terrier, Christophe, Nordmann, Patrice, Poirel, Laurent   +2 more
core   +1 more source

Successful Treatment with Sulbactam-Durlobactam for Severe Acute Pancreatitis Complicated by Extensively Drug-Resistant Acinetobacter baumannii Infection at Multiple Sites: A Case Report

Infection and Drug Resistance
Zhengmao Ge, Li Li, Longxin Wang, Dengke Liu, Yupeng Liu Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, Dalian, 116021, People’s Republic of ChinaCorrespondence: Yupeng Liu, Department of Critical Care ...
Ge Z, Li L, Wang L, Liu D, Liu Y
doaj  

Clinical Characteristics and in vitro Activities of Sulbactam-durlobactam and Cefiderocol against Carbapenem-resistant Acinetobacter baumannii Infections in Chinese Children: A Multicenter Study

Objective To systematically characterize the carbapenem-resistant Acinetobacter baumannii (CRAB) infections in children and to identify risk factors associated with 28-day mortality. We evaluated the
Wei Xie, Zhenlong Wang, Chunmei Jing, jingyi Dong, lijun zhang, Gaihuan Zheng, Zhongzheng Xiong, Cai Wang, Yupei Xiang   +8 more
core   +1 more source

Therapeutic challenges and emerging strategies against carbapenem-resistant Acinetobacter baumannii

Current Research in Microbial Sciences
Carbapenem-resistant Acinetobacter baumannii (CRAB) remains a formidable clinical challenge, driven by limited therapeutic options and multifaceted resistance mechanisms.
Chunhong Yang, Jing Li, Xiao Luo, Zhangyong Song, Jinping Zhang   +4 more
doaj   +1 more source

Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs

Emerging Infectious Diseases
The US Food and Drug Administration recognizes the unmet medical need for antibacterial drugs to treat serious bacterial diseases caused by resistant pathogens for which effective therapies are limited or lacking.
Mayurika Ghosh, Dmitri Iarikov, Xiaojing (Karen) Qi, Daniel Rubin, Simone Shurland, Avery Goodwin, Xiaohui Wei, Dakshina Chilukuri, Owen McMaster, Terry Miller, Peter Kim, Adam Sherwat   +11 more
doaj   +1 more source

Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii

Frontiers in Cellular and Infection Microbiology
Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion of CRAB infections is high, appropriate treatment ...
Siqin Zhang, Lingfang Di, Yan Qi, Xiang Qian, Siwei Wang   +4 more
doaj   +1 more source